1. Kjerulff KH, Langenberg P, Seidman JD, Stolley PD, Guzinski GM. Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis. J Reprod Med. 1996; 41(7): 483-490.
2. Huyck KL, Panhuysen CIM, Cuenco KT, et al. The impact of race as a risk factor for symptom severity and age at diagnosis of uterine leiomyomata among affected sisters. Am J Obstet Gynecol. 2008; 198(2): 168.e1-168.e9. doi: 10.1016/j.ajog.2007.05.038
3. Rezk A, Kahn J, Singh M. Fertility sparing management. In: Uterine Fibroids. Treasure Island (FL), USA: StatPearls Publishing; 2022. https://www.ncbi.nlm.nih.gov/books/NBK574504/. Accessed November 11, 2023.
4. Yang Q, Mas A, Diamond MP, Al-Hendy A. The mechanism and function of epigenetics in uterine leiomyoma Development. Reprod Sci. 2016; 23(2): 163-175. doi: 10.1177/1933719115584449
5. Jamaluddin MFB, Nahar P, Tanwar PS. Proteomic characterization of the extracellular matrix of human uterine fibroids. Endocrinology. 2018; 159(7): 2656-2669. doi: 10.1210/en.2018-00151
6. Ratajczak MZ, Bujko K, Mack A, Kucia M, Ratajczak J. Cancer from the perspective of stem cells and misappropriated tissue regeneration mechanisms. Leukemia. 2018; 32(12): 2519-2526. doi: 10.1038/s41375-018-0294-7
7. Chaudhry SR, Liman MNP; Peterson DC. Anatomy, Abdomen and Pelvis: Stomach. Treasure Island (FL), USA: StatPearls Publishing. 2021. Webstie. https://www.ncbi.nlm.nih.gov/books/ NBK482334/. Accessed November 11, 2023.
8. Brakta S, Mas A, Al-Hendy A. The ontogeny of myometrial stem cells in OCT4-GFP transgenic mouse model. Stem Cell Res Ther. 2018; 9(1): 333. doi: 10.1186/s13287-018-1079-7
9. Bozorgmehr M, Gurung S, Darzi S, et al. Endometrial and menstrual blood mesenchymal stem/stromal cells: Biological properties and clinical application. Front Cell Dev Biol. 2020; 8: 497. doi: 10.3389/fcell.2020.00497
10. Ono M, Bulun SE, Maruyama T. Tissue-specific stem cells in the myometrium and tumor-initiating cells in leiomyoma. Bio Reprod. 2014; 91(6): 149. doi: 10.1095/biolreprod.114.123794
11. Mas A, Cervello I, Gil-Sanchis C, Simón C. Current understanding of somatic stem cells in leiomyoma formation. Fertil Steril. 2014; 102(3): 613-620. doi: 10.1016/j.fertnstert.2014.04.051
12. Al-Hendy A, Myers ER, Stewart E. Uterine fibroids: Burden and unmet medical need. Semin Reprod Med. 2017; 35(6): 473-480. doi: 10.1055/s-0037-1607264
13. Sheaffer KL, Kim R, Aoki R, et al. DNA methylation is required for the control of stem cell differentiation in the small intestine. Genes Dev. 2014; 28(6): 652-664. doi: 10.1101/gad.230318.113
14. Mazloumi Z, Farahzadi R, Rafat A, et al. Effect of aberrant DNA methylation on cancer stem cell properties. Exp Mol Pathol. 2022; 125: 104757. doi: 10.1016/j.yexmp.2022.104757
15. Wang Y, Cardenas H, Fang F, et al. Epigenetic targeting of ovarian cancer stem cells. Cancer Res. 2014; 74(17): 4922-4936. doi: 10.1158/0008-5472.CAN-14-1022
16. Liu S, Yin P, Xu J, et al. Targeting DNA methylation depletes uterine leiomyoma stem cell-enriched population by stimulating their differentiation. Endocrinology. 2020; 161(10): bqaa143. doi: 10.1210/endocr/bqaa143
17. Mas A, Cervelló I, Gil-Sanchis C, et al. Identification and characterization of the human leiomyoma side population as putative tumor-initiating cells. Fertil Steril. 2012; 98(3): 741-751.e6. doi: 10.1016/j.fertnstert.2012.04.044
18. Moravek MB, Yin P, Ono M, et al. Ovarian steroids, stem cells and uterine leiomyoma: Therapeutic implications. Hum Reprod Update. 2015; 21(1): 1-12. doi: 10.1093/humupd/dmu048
19. Mas A, Stone L, O’Connor PM, et al. Developmental exposure to endocrine disruptors expands murine myometrial stem cell compartment as a prerequisite to leiomyoma tumorigenesis. Stem Cells. 2017; 35(3): 666-678. doi: 10.1002/stem.2519
20. Ono M, Qiang W, Serna VA, et al. Role of stem cells in human uterine leiomyoma growth. PLoS One. 2012; 7(5): e36935. doi: 10.1371/journal.pone.0036935
21. Mas A, Cervelló I, Fernández-Álvarez A, et al. Overexpression of the truncated form of High Mobility Group A proteins (HMGA2) in human myometrial cells induces leiomyoma-like tissue formation. Mol Hum Reprod. 2015; 21(4): 330-338. doi: 10.1093/molehr/gau114
22. Zhou S, Yi T, Shen K, Zhang B, Huang F, Zhao X. Hypoxia: The driving force of uterine myometrial stem cells differentiation into leiomyoma cells. Med Hypotheses. 2011; 77(6): 985-986. doi: 10.1016/j.mehy.2011.08.026
23. Maruyama T, Ono M, Yoshimura Y. Somatic stem cells in the myometrium and in myomas. Semin Reprod Med. 2013; 31(01): 77- 81. doi: 10.1055/s-0032-1331801
24. Liu B, Chen G, He Q, et al. An HMGA2-p62-ERα axis regulates uterine leiomyomas proliferation. FASEB J. 2020; 34(8): 10966-10983. doi: 10.1096/fj.202000520R
25. Ono M, Maruyama T, Masuda H, et al. Side population in human uterine myometrium displays phenotypic and functional characteristics of myometrial stem cells. Proc Natl Acad Sci U S A. 2007; 104(47): 18700-18705. doi: 10.1073/pnas.0704472104
26. Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A. Oxygen in stem cell biology: A critical component of the stem cell niche. Cell Stem Cell. 2010; 7(2): 150-161. doi: 10.1016/j. stem.2010.07.007
27. Red-Horse K, Zhou Y, Genbacev O, et al. Trophoblast differentiation during embryo implantation and formation of the maternal-fetal interface. J Clin Invest. 2004; 114(6): 744-754. doi: 10.1172/JCI22991
28. Cervello I, Gil-Sanchis C, Mas A, et al. Human endometrial side population cells exhibit genotypic, phenotypic and functional features of somatic stem cells. PLoS One. 2010; 5(6): e10964. doi: 10.1371/journal.pone.0010964
29. Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: Ultrasound evidence. Am J Obstet Gynecol. 2003; 188(1): 100-107. doi: 10.1067/mob.2003.99
30. Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract Res Clin Obstet Gynaecol. 2008; 22(4): 571-588. doi: 10.1016/j.bpobgyn.2008.04.002
31. Wallach EE, Vlahos NF. Uterine myomas: An overview of development, clinical features, and management. Obstet Gynecol. 2004; 104(2): 393-406. doi: 10.1097/01.AOG.0000136079.62513.39
32. Ono M, Qiang W, Serna VN, et al. Role of stem cells in human uterine leiomyoma growth. PLoS One. 2012; 7(5): e36935. doi: 10.1371/journal.pone.0036935
33. Ono M, Yin P, Navarro A, et al. Paracrine activation of WNT/β-catenin pathway in uterine leiomyoma stem cells promotes tumor growth. Proc Natl Acad Sci U S A. 2013. 110(42): 17053-17058. doi: 10.1073/pnas.1313650110
34. Zhang P, Zhang C, Hao J, et al. Use of X-chromosome inactivation pattern to determine the clonal origins of uterine leiomyoma and leiomyosarcoma. Hum Pathol. 2006; 37(10): 1350-1356. doi: 10.1016/j.humpath.2006.05.005
35. Linder D, Gartler SM. Glucose-6-phosphate dehydrogenase mosaicism: utilization as a cell marker in the study of leiomyomas. Science. 1965; 150(3692): 67-69. doi: 10.1126/science.150.3692.67
36. Liu S, Yin P, Xu J, et al. Progesterone receptor-DNA methylation crosstalk regulates depletion of uterine leiomyoma stem cells: A potential therapeutic target. Stem Cell Reports. 2021; 16(9): 2099-2106. doi: 10.1016/j.stemcr.2021.07.013
37. Navarro A, Yin P, Monsivais D, et al. Genome-wide DNA methylation indicates silencing of tumor suppressor genes in uterine leiomyoma. PLoS One. 2012; 7(3): e33284. doi: 10.1371/journal.pone.0033284
38. Georgieva B, Milev I, Minkov I, Dimitrova I, Bradford AP, Baev V. Characterization of the uterine leiomyoma microRNAome by deep sequencing. Genomics. 2012; 99(5): 275-281. doi: 10.1016/j.ygeno.2012.03.003
39. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002; 30(4): 406-410. doi: 10.1038/ng849
40. Mäkinen N, Mehine M, Tolvanen J, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011; 334(6053): 252-255. doi: 10.1126/science.1208930
41. de Graaff MA, Cleton-Jansen A-M, Szuhai K, Bovée JVMG. Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity. Hum Pathol. 2013; 44(8): 1597-1604. doi: 10.1016/j. humpath.2013.01.006
42. Rieker RJ, Agaimy A, Moskalev EA, et al. Mutation status of the mediator complex subunit 12 (MED12) in uterine leiomyomas and concurrent/metachronous multifocal peritoneal smooth muscle nodules (leiomyomatosis peritonealis disseminata). Pathology, 2013. 45(4): 388-392. doi: 10.1097/PAT.0b013e328360bf97
43. Ravegnini G, Mariño-Enriquez A, Slater J, et al. MED12 mutations in leiomyosarcoma and extrauterine leiomyoma. Mod Pathol. 2013; 26(5): 743-749. doi: 10.1038/modpathol.2012.203
44. Heinonen H-R, Sarvilinna NS, Sjöberg J, et al. MED12 mutation frequency in unselected sporadic uterine leiomyomas. Fertil Steril. 2014; 102(4): 1137-1142. doi: 10.1016/j.fertnstert.2014.06.040
45. Markowski DN, Bartnitzke S, Löning T, Drieschner N, Helmke BM, Bullerdiek J. MED12 mutations in uterine fibroids—their relationship to cytogenetic subgroups. Int J Cancer. 2012; 131(7): 1528-1536. doi: 10.1002/ijc.27424
46. Shaik NA, Lone WG, Khan IA, et al. Detection of somatic mutations and germline polymorphisms in mitochondrial DNA of uterine fibroids patients. Genet Test Mol Biomarkers. 2011; 15(7- 8): 537-541. doi: 10.1089/gtmb.2010.0255
47. Mehine M, Kaasinen E, Mäkinen N, et al. Characterization of uterine leiomyomas by whole-genome sequencing. N Engl J Med. 2013; 369(1): 43-53. doi: 10.1056/NEJMoa1302736
48. Hodge JC, Pearce KE, Clayton AC, Taran FA, Stewart EA. Uterine cellular leiomyomata with chromosome 1p deletions represent a distinct entity. Am J Obstet Gynecol. 2014; 210(6): 572.e1- 572.e7. doi: 10.1016/j.ajog.2014.01.011
49. Klemke M, Meyer A, Maliheh Hashemi Nezhad, et al. Overexpression of HMGA2 in uterine leiomyomas points to its general role for the pathogenesis of the disease. Genes Chromosomes Cancer. 2009. 48(2): 171-8. doi: 10.1002/gcc.20627
50. Mehine M, Kaasinen E, Heinonen H-R, et al. Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers. Proc Natl Acad Sci U S A. 2016; 113(5): 1315-1320. doi: 10.1073/pnas.1518752113
51. Nezhad MH, Drieschner N, Helms S, et al. 6p21 rearrangements in uterine leiomyomas targeting HMGA1. Cancer Genetics and Cytogenet. 2010; 203(2): 247-252. doi: 10.1016/j.cancergencyto.2010.08.005
52. Schoenmakers, E.F.P.M., et al. Identification of CUX1 as the recurrent chromosomal band 7q22 target gene in human uterine leiomyoma. Genes, Chromosomes Cancer. 2013. 52(1): 11-23. doi: 10.1002/gcc.22001
53. Nozu K, Minamikawa S, Yamada S, et al. Characterization of contiguous gene deletions in COL4A6 and COL4A5 in Alport syndrome-diffuse leiomyomatosis. J Human Genet. 2017; 62(7): 733-735. doi: 10.1038/jhg.2017.28
54. Laganà AS, Vergara D, Favilli A, et al. Epigenetic and genetic landscape of uterine leiomyomas: A current view over a common gynecological disease. Arch Gynecol Obstet. 2017; 296(5): 855-867. doi: 10.1007/s00404-017-4515-5
55. Miozzo, M., V. Vaira, and S.M. Sirchia, Epigenetic alterations in cancer and personalized cancer treatment. Future Oncology, 2015. 11(2): 333-348. doi: 10.2217/fon.14.237
56. Styer AK, Rueda BR. The epidemiology and genetics of uterine leiomyoma. Best Pract Res Clin Obstet Gynaecol. 2016. 34: 3-12. doi: 10.1016/j.bpobgyn.2015.11.018
57. Maekawa, R., Shun Sato, Yoshiaki Yamagata, et al. Genomewide DNA methylation analysis reveals a potential mechanism for the pathogenesis and development of uterine leiomyomas. PLoS One. 2013; 8(6): e66632. doi: 10.1371/journal.pone.0066632
58. George JW, Fan H, Johnson B, et al. Integrated epigenome, exome, and transcriptome analyses reveal molecular subtypes and homeotic transformation in uterine fibroids. Cell Reports. 2019; 29(12): 4069-4085.e6. doi: 10.1016/j.celrep.2019.11.077
59. Liu S, Yin P, Kujawa SA, Coon JS, Okeigwe I, Bulun SE. Progesterone receptor integrates the effects of mutated MED12 and altered DNA methylation to stimulate RANKL expression and stem cell proliferation in uterine leiomyoma. Oncogene. 2019; 8(15): 2722-2735. doi: 10.1038/s41388-018-0612-6
60. Ali M, Ciebiera M, Vafaei S, et al. Progesterone signaling and uterine fibroid pathogenesis; Molecular mechanisms and potential therapeutics. Cells. 2023; 12(8): 1117. doi: 10.3390/cells12081117
61. Vaiman D. Towards an epigenetic treatment of leiomyomas? Endocrinology. 2020; 161(12): bqaa172. doi: 10.1210/endocr/ bqaa172
62. Albert M, Helin K. Histone methyltransferases in cancer. Semin Cell Dev Biol. 2010; 21(2): 209-220. doi: 10.1016/j. semcdb.2009.10.007
63. Wei L-H, Torng P-L, Hsiao S-M, Jeng Y-M, Chen M-W, Chen C-A. Histone deacetylase 6 regulates estrogen receptor α in uterine leiomyoma. Reprod Sci. 2011; 18(8): 755-762. doi: 10.1177/1933719111398147
64. Segars JH, Al-Hendy A. Uterine leiomyoma: New perspectives on an old disease. Semin Reprod Med. 2017; 35(06): 471-472. doi: 10.1055/s-0037-1606569
65. Borahay MA, Al-Hendy A, Kilic GS, Boehning D. Signaling pathways in leiomyoma: Understanding pathobiology and implications for therapy. Mol Med. 2015; 21(1): 242-256. doi: 10.2119/molmed.2014.00053
66. Chuang TD, Rehan A, Khorram O, Functional role of the long noncoding RNA X-inactive specific transcript in leiomyoma pathogenesis. Fertil Steril. 2021; 115(1): 238-247. doi: 10.1016/j.fertnstert.2020.07.024
67. Ciarmela P, Petraglia F. New epigenetic mechanism involved in leiomyoma formation. Fertili Steril. 2021; 115(1): 94-95. doi: 10.1016/j.fertnstert.2020.09.143
68. Rinaldi L, Benitah SA. Epigenetic regulation of adult stem cell function. FEBS J. 2015; 282(9): 1589-1604. doi: 10.1111/ febs.12946
69. Mazzarella L, Jørgensen HF, Soza-Ried J, et al. Embryonic stem cell–derived hemangioblasts remain epigenetically plastic and require PRC1 to prevent neural gene expression. Blood. 2011; 117(1): 83-87. doi: 10.1182/blood-2010-03-273128
70. Laugesen A, Helin K. Chromatin repressive complexes in stem cells, development, and cancer. Cell Stem Cell. 2014; 14(6): 735-751. doi: 10.1016/j.stem.2014.05.006
71. Ezura, Y., et al. Methylation status of CpG islands in the promoter regions of signature genes during chondrogenesis of human synovium–derived mesenchymal stem cells. Arthritis Rheum. 2009; 60(5): 1416-1426. doi: 10.1002/art.24472
72. Bulun SE. Uterine fibroids. N Engl J Med. 2013; 369(14): 1344- 1355. doi: 10.1056/NEJMra1209993
73. Linehan WM, Rouault TA. Molecular pathways: Fumarate hydratase-deficient kidney cancer—targeting the Warburg effect in cancer. Clin Cancer Res. 2013; 19(13): 3345-3352. doi: 10.1158/1078-0432.CCR-13-0304
74. Maruyama T, Ono M, Yoshimura Y. Somatic stem cells in the myometrium and in myomas. Semin Reprod Med. 2013; 31(1): 77- 81. doi: 10.1055/s-0032-1331801
75. Szotek PP, Chang HL, Zhang L, et al. Adult mouse myometrial label-retaining cells divide in response to gonadotropin stimulation. Stem Cells. 2007; 25(5): 1317-1325. doi: 10.1634/ stemcells.2006-0204
76. Ono M, Yin P, Navarro A, et al. Inhibition of canonical WNT signaling attenuates human leiomyoma cell growth. Fertil Steril. 2014; 101(5): 1441-1449. e1. doi: 10.1016/j.fertnstert.2014.01.017
77. Włodarczyk M, Nowicka G, Ciebiera M, Ali M, Yang Q, AlHendy A. Epigenetic regulation in uterine fibroids—the role of ten-eleven translocation enzymes and their potential therapeutic application. Int J Mol Sci. 2022; 23(5): 2720. doi: 10.3390/ ijms23052720
78. Ali M, Bariani MV, Vafaei S, et al. Prevention of uterine fibroids: Molecular mechanisms and potential clinical application. J Endometr Uterine Disord. 2023; 1: 100018. doi: 10.1016/j. jeud.2023.100018
79. Bertsch E, Qiang W, Zhang Q, et al. MED12 and HMGA2 mutations: Two independent genetic events in uterine leiomyoma and leiomyosarcoma. Mod Pathol. 2014; 27(8): 1144-1153. doi: 10.1038/modpathol.2013.243
80. Schwetye KE, Pfeifer JD, Duncavage EJ. MED12 exon 2 mutations in uterine and extrauterine smooth muscle tumors. Hum Pathol. 2014; 45(1): 65-70. doi: 10.1016/j.humpath.2013.08.005
81. Sá MJN, Fieremans N, de Brouwer APM, et al. Deletion of the 5’ exons of COL4A6 is not needed for the development of diffuse leiomyomatosis in patients with Alport syndrome. J Med Genet. 2013; 50(11): 745-753. doi: 10.1136/jmedgenet-2013-101670
82. Vanharanta S, Pollard PJ, Lehtonen HJ, et al. Distinct expression profile in fumarate-hydratase-deficient uterine fibroids. Hum Mol Genet. 2006; 15(1): 97-103. doi: 10.1093/hmg/ddi431